Apixaban to prevent blood clots in outpatient brain tumor patients
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This trial tests whether apixaban, a blood thinner, can prevent dangerous blood clots in people with a certain type of malignant brain tumor who are getting radiation and chemotherapy. It may help lower the risk of clots like leg clots or lung clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have malignant glioma that is WHO grade 4 (like glioblastoma or astrocytoma), confirmed by recent biopsy or surgery
- You are 18 years or older and able to give informed consent
- Your overall ability to do daily activities is moderate to strong (Karnofsky score 60–100)
- Your kidney function and blood counts meet study lab thresholds (platelets ≥ 100,000 and GFR ≥ 25)
- You are planning to start radiation and chemotherapy as part of your treatment
- You have not had a DVT, pulmonary embolism, or cerebral vein clot in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
This trial tests giving a precise dose of radiation directly to the tumor area during surgery for newly diagnosed glioblastoma. The goal is to destroy remaining tumor cells immediately after removal, which may improve outcomes.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
This Phase 2 study tests a protective approach using bevacizumab (a medicine that blocks VEGF) while doctors carefully increase the dose in people with glioblastoma. It’s meant to help control tumor growth and possibly reduce certain risks that can happen with blood-vessel–targeting treatments.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.